SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022. Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are … Read more
– New activator in the GEMS (Gene Expression Modulation System) Platform addresses limitations of existing therapy modalities –– Persistent activation of genes may provide permanent cure for diseases such as haploinsufficient diseases –– Tunable protein expression mitigates the risk of toxic overexpression – SOUTH SAN FRANCISCO, Calif. — October 31, 2022 — Epic Bio, a biotechnology company … Read more
SOUTH SAN FRANCISCO, Calif. — October 24, 2022 — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 – 29, 2022. ICEB 2022 Presentation Details: Poster Presentation Title: GEMS: … Read more